FibroBiologics, Inc. (FBLG): Nasdaq/NYSE listing notice — FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026

FibroBiologics, Inc.

Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.
Company has until Feb 2, 2026 to regain compliance by having MVLS close at $35M+ for 10 consecutive business days.
No immediate impact on listing; stock continues trading on Nasdaq Capital Market under symbol FBLG.
If compliance is not regained by Feb 2, 2026, Nasdaq may initiate delisting, subject to appeal.
Company will monitor MVLS and consider available options to address the deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

August 4, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it does not meet the requirement in Nasdaq Listing Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35.0 million that is required for continued listing on The Nasdaq Capital Market (the “Notice”). The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market subject

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-105807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.